Valeant Pharmaceuticals
This article was originally published in The Rose Sheet
Executive Summary
Firm will enter into lease for "state-of-the-art, 45,000-square-foot facility that includes a manufacturing plant completed in 2007 specializing in topical formulations" as part of its acquisition of Canadian cosmeceutical maker Laboratoire Dr. Renaud. Valeant Canada Limited will pay approximately $21.69 mil. for the company, which posts annual sales of roughly $10.37 mil., in deal expected to close before year-end. Transaction is expected to be accretive in 2010, according to Dec. 7 release. "This acquisition is part of our continued efforts to build a leading dermatology business by adding respected brand names in our select regions," states Valeant Chairman and CEO J. Michael Pearson. Dr. Renaud "enjoys a high degree of loyalty from esthetic clinics and spas, and we believe that Valeant will gain immediate entrée into the cosmeceutical market in Canada," Pearson adds. Aliso Viejo, Calif.-based Valeant, which markets Kinerase skin care, picked up Private Formula International in October for roughly $69 million, giving it a dominant market presence in Australia (1"The Rose Sheet" Oct. 5, 2009)
You may also be interested in...
Valeant nabs Australian skin care
Aliso Viejo, Calif.-based Valeant Pharmaceuticals International announces agreement to buy skin-care firm Private Formula International Holdings Pty Limited for approximately $69 million. With deal Valeant gains global rights to top-selling Australian skin-care line Dr. LeWinn's, new anti-aging Hissyfit products, and nail-strengthener line Revitanail, called Renunail in the U.S. and U.K. Dr. LeWinn's has distribution in more than 2,500 pharmacies and annual sales of $27 million. Valeant will issue 162,500 shares of its common stock as part of the deal, which will be escrowed for four years subject to Valeant indemnity claims. "The acquisition will allow Valeant Australia to become a leading dermatology company in Australia with brands that are complementary to our current portfolio and will dramatically increase our presence in the pharmacy over-the-counter channel," stated Valeant Chair and CEO J. Michael Pearson. The transaction is expected to close in early October. Valeant has expanded its dermatology holdings through recent acquisitions of Dow Pharmaceutical Sciences and Coria Laboratories (1"The Rose Sheet" April 13, 2009; 2"The Rose Sheet" Sept. 22, 2008)
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.